Joseph Kovalchin

TL;DR: It is found that fatty acids (FAs) compete with FcRn, revealing a clash between ligand binding and recycling, and that high-affinity HSA variants have significantly increased circulating half-lives in mice and monkeys.

TL;DR: This rationally designed antagonist represents a unique approach to therapeutic design that can potentially be exploited for other β-trefoil family proteins in the IL-1 and FGF families.

TL;DR: This work investigated the binding, functional activity, and in vitro/in vivo vascular effects of lasmiditan and compared it to sumatriptan to assess the selectivity and cardiovascular effects of the drug.

TL;DR: These results support use of an adapted, multiple-challenge, direct conjunctival allergen model to assess efficacy of EBI-005 in late phase AC and show statistically significant improvements in clinically meaningful symptoms for moderate-to-severe AC subjects.

TL;DR: In vitro and in vivo nonclinical Investigational New Drug (IND)-enabling studies of EBI-005, a novel protein chimera of IL-1&bgr; and IL-2 receptor antagonist (IL-1Ra or anakinra) that potently binds IL- 1R1 and blocks signaling provide an assessment of receptor affinity, drug bioavailability, immunogenic response, safety, and tolerability in mice and rabbits.